Publications by authors named "Lyubov A Orlova"
Article Synopsis
- The conventional live smallpox vaccine, based on the vaccinia virus (VACV), has limitations due to high reactogenicity, prompting the need for safer VACV variants with better immune responses.
- This study explores low-dose VACV variants with genetic modifications that boost immune responses, specifically looking at humoral and T cell-mediated immunity in mice.
- The research found that the LIVP-A34R*-dA35R variant produced the strongest T cell-mediated immunity and higher antibody levels compared to the parental LIVP strain, suggesting that combining gene modification and deletion enhances the vaccine's effectiveness.
Despite the fact that a range of vaccines against COVID-19 have already been created and are used for mass vaccination, the development of effective, safe, technological, and affordable vaccines continues. We have designed a vaccine that combines the recombinant protein and DNA vaccine approaches in a self-assembled particle. The receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 was conjugated to polyglucin:spermidine and mixed with DNA vaccine (pVAXrbd), which led to the formation of particles of combined coronavirus vaccine (CCV-RBD) that contain the DNA vaccine inside and RBD protein on the surface.
View Article and Find Full Text PDFOne of the key stages in the development of mRNA vaccines is their delivery. Along with liposome, other materials are being developed for mRNA delivery that can ensure both the safety and effectiveness of the vaccine, and also facilitate its storage and transportation. In this study, we investigated the polyglucin:spermidine conjugate as a carrier of an mRNA-RBD vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
View Article and Find Full Text PDF